Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NYSE: BIO

Bio-Rad Laboratories, Inc.

Healthcare | Medical - Devices
$296.86 +21.06 (+7.64%) as of 2026-07-15 02:33 UTC
Market Cap$8.0B
Volume272.0K
EPS (TTM)$27.85

Bio-Rad Laboratories, Inc. (NYSE: BIO) is a $8.0B medical - devices company trading at $296.86 (+7.6% today) — 10.7× trailing earnings. Figures from SEC EDGAR and market feeds; updated 2026-07-15 02:33 UTC.

52-Week Range
Low $274.89High $312.85

What Bio-Rad Laboratories, Inc. does

Bio-Rad Laboratories is a multinational company that develops, manufactures, and markets instruments, systems, reagents, and consumables for life science research and clinical diagnostics. The company operates through two segments: Life Science, which serves research institutions and biopharmaceutical manufacturers with products for separating and analyzing biological materials, and Clinical Diagnostics, which supplies test systems and reagents to clinical laboratories worldwide.

Summarized from Bio-Rad Laboratories, Inc.’s SEC filings · Read the filing ↗

Key facts
Quote
Price$296.86
Change (1D)+21.06 (+7.64%)
Market cap$8.0B
Volume272.0K shares
52-week range$274.89 – $312.85
Valuation
P/E (TTM)10.66×
EV/EBITDA40.90×
EPS (TTM)$27.85
Price/book1.08×
Return on equity10.20%
Debt/equity0.16
Returns
52-week return+8.0%
Revenue, margins & earnings
FY2021 Revenue: $2.92B — margin split not shown (non-operating gains)FY2021: net income $4.25B exceeded revenue $2.92B by $1.33B — non-operating gains (e.g. asset sales), not operating profit$2.92BFY2021FY2022: net loss $3.63B on revenue $2.80B$2.80BFY2022FY2023: net loss $637M on revenue $2.67B$2.67BFY2023FY2024: net loss $1.84B on revenue $2.57B$2.57BFY2024FY2025 Revenue: $2.58B — margin split not shown (non-operating gains)$2.58BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net income above revenue (non-operating gains)
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →
Gold cap: net income exceeded revenue that year from non-operating gains (e.g. asset sales), not operating profit.
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-05-13
  • 2026-05-13ENGELHARDT EVA ANETTEEVP, President, CDGSELL-550$135.6K
  • 2026-04-28Lakkaraju Roop KalyanEVP, Chief Financial OfficerF-420$120.9K
  • 2026-04-28Lakkaraju Roop KalyanEVP, Chief Financial OfficerM1,078—
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • First Eagle Investment Management, LLC2,602,772$725.52M+1.3%
  • VANGUARD GROUP INC1,746,312$529.12M-2.6%
  • BlackRock, Inc.1,491,692$415.81M-11.3%
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does Bio-Rad Laboratories, Inc. do?

Bio-Rad Laboratories is a multinational company that develops, manufactures, and markets instruments, systems, reagents, and consumables for life science research and clinical diagnostics.

What is BIO's valuation?

BIO trades at $296.86, 10.66× trailing earnings, 40.90× EV/EBITDA, as of 2026-07-15.

When did BIO last file with the SEC?

Bio-Rad Laboratories, Inc.'s most recent SEC filing on record is a 10-Q filed 2026-04-30. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-15 02:33 UTC. This page is also available as JSON at /api/data?ticker=BIO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BIO and 3,500+ tickers.

Create a free account — keep BIO
For your agent
GET /api/data?ticker=BIO

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt